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ORIGINAL ARTICLE
INTRODUCTION
Colorectal carcinoma (CRC) is the third major
malignancy worldwide after lung cancer and breast
cancer and it is the third leading cause of cancer death
from all cancers.1 Until now, the curative treatment is
surgical resection although adjuvant treatment has been
growing rapidly. However, there is little that can
improve the survival rate of patients in advanced stages
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ABSTRACT
Background: Adenomatous polyposis coli (APC) gene mutation was found in up to 80% of cases of
sporadic colorectal cancers and adenomas. Loss of APC protein function has been known as one of the
early process in colorectal carcinogenesis. This event leads to the accumulation of beta catenin in the
cytoplasm and nucleus and subsequently activates target genes that regulate cell proliferation and
apoptosis. The aim of this study was to investigate the alteration of subcellular beta catenin expression
in the progression of colorectal cancer.
Method: This cross-sectional study was conducted with 30 paraffin-embedded tissue sections each of
normal colorectal mucosa, adenomas and carcinomas. Alteration of beta catenin expression in
membranous, cytoplasmic, and nuclear compartments were evaluated by immunohistochemical staining.
Results: Beta catenin immunoreactivity was detected in all cases, of which 87 (96.7%) cases showed
membranous expression, 78 (86.7%) cases had cytoplasmic and 51 cases (56.7%) had nuclear expression.
Such results were statistically significant (p < 0.000). All normal colorectal epithelium showed membranous
beta catenin expression with 18 (60.0%) cases showed cytoplasmic and no nuclear beta catenin expression
was found.  Strong cytoplasmic expression was found in 17 (56.7%) adenomas and 25 (83.3%) carcinomas;
while strong nuclear expression was found in 12 (40.0%) adenomas and 17 (56.7%) carcinomas. There
was no statistical significant association between beta catenin expression in the membranous, cytoplasmic
and nuclear compartment with the degree of dysplasia or differentiation of tumor (p > 0.05).
Conclusion: Altered subcellular expression of beta catenin occurs as the oncogenic process develops
from adenoma into carcinoma. Such finding reflects the importance of beta-catenin in colorectal
carcinogenesis.
Keywords: beta catenin, colorectal cancer, adenoma, colorectal cancer progression
of the CRC.2 The detection of new cases in the early
stages should be developed as a preventive action that
can reduce morbidity and mortality in CRC patients.3
Colorectal carcinogenesis is a multistep processes
that occurs due to genetic changes from normal mucosa
to adenoma and then carcinoma. This pathway requires
the accumulation of genetic changes which proceeded
by the inactivation of tumor suppressor gene
adenomatous polyposis coli (APC).4 Beta catenin has
recently been the object of increasing interest because
of the discovery of additional functions of this protein
apart from its well-known role in cell adhesion.5 The
implication of beta catenin in the transduction of
Wingless/Wnt-dependent cell–cell signaling has been
demonstrated.6 Furthermore, beta catenin may also
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play a direct role in colorectal carcinogenesis because
it binds the product of the tumor supressor gene APC.
Glycogen synthase kinase-3 beta (GSK-3-beta) and
wild-type APC regulate the level of free cytoplasmic
beta catenin by promoting its degradation through the
ubiquitin proteasome pathway.5
When APC is mutated, as occurs in 85% of CRCs
and adenomas, beta catenin accumulates in the
cytoplasm and can translocate into the nucleus, where
it binds transcription factors of the T-cell factor (TCF)/
lymphoid enhancer factor (LEF) gene family and
activates the expression of target genes. Therefore, it
is proposed that beta catenin plays a dual role, not only
in the formation and maintenance of cells interactions
but also in the regulation of gene activity with a dominant
oncogenic effect on carcinogenesis.5,6
Since it is important to understand beta catenin
nuclear localization in the development of colorectal
cancers, we have conducted a detailed comparison of
beta catenin distribution in normal colorectal mucosa,
adenomas and carcinomas
METHOD
Human tissue samples were obtained from surgical
resection of 30 patients with colorectal cancer and
colonic biopsies of 30 patients with adenomas from
the Department of Anatomical Pathology, University
of Indonesia. Thirty histologically normal colorectal
mucosa of the resection margin were also included in
this study. Serial sections were cut at 4 ìm thickness
from paraffin-embedded blocks and placed on
poly-L-lysin-coated slides. One haematoxylin/eosin
stained slide was reviewed for histological classification
and other slides were used for immunohistochemical
analysis.
Beta catenin immunostaining: in brief, sections were
deparaffinized and rehydrated in graded alcohol.
Endogenous peroxidase activity was blocked with
0.5% hydrogen peroxide in methanol for 20 minutes.
Antigen retrieval was used by microwave treatment,
Dilution was 1:100 for beta catenin (Novocastra, United
Kingdom). Biotinylated universal antiserum (Starr Trek
HRP Universal, Biocare Medical, CA) was used as
the secondary antibody. After washing, the slides were
incubated for 20 minutes at room temperature with
Trekavidin HRP label (Starr Trek HRP Universal
Biomedical CA) and developed for 10 minutes using
diaminobenzidine as chromogen. After rinsing in water,
the sections were counterstained with Meyer
haematoxylin, dehydrated, and coverslipped.
Appropriate positive and negative controls were
included in each run of immunohistochemistry.
Beta catenin evaluation: normal colonic epithelial
cells served as internal positive controls with
membrane staining (figure 1). Cytoplasmic, nuclear,
and membrane expressions were recorded separately.
The percentage of cells with membranous, cytoplasmic
and nuclear positivity was graded as follows:
(0) < 5%, (1) 5–25%, (2) 26–50%, (3) 51–75%,
(4) > 75%, and the staining intensity was graded as
(0) negative for no expression, or (1) positive for
positive expression. Cytoplasmic staining was graded
into 3 categories: (0) Negative, no detectable staining,
(1) Weak, but still detectable staining, (2) Heavy
staining, intense. The nuclear staining was also graded
to into 3 categories: (0) Negative, only blue staining
seen, (1) Weak, blue staining clearly seen through
brown staining, (2) Heavy staining, blue scarcely seen
through brown staining, nuclei appear darker than the
cytoplasm, or no blue seen through brown staining.
Immunohistochemistry scores obtained by multiplying
the “percentage of positive cells” by the “staining
intensity” and expressed as negative (score 0), weak
(score 1-4), strong (score 5-8).
All immunohistochemically stained slides were
evaluated using regular light microscopy by one of the
investigators who had been blinded from any other
clinical and laboratory data. A second observer
examined 30 cases randomly, and kappa coefficients
for agreement in these 30 cases were as follows: 0.525
for cytoplasmic positivity, 0.753 for nuclear positivity,
0.737 for membrane positivity, which indicated overall
moderate to substantial agreement.
Kruskal-Wallis test was used to evaluate the
relationship between the expression of beta catenin as
well as progression and expression of beta catenin and
its differentiation. Mann-Whitney test was used to
evaluate the relationship between the expression of
beta catenin and degree of dysplasia. All statistical tests
were performed by using the SPSS package version
13.0 (SPSS, Chicago, IL), p < 0.05 was considered
significant.
RESULTS
The clinicopathologic data are summarized in table
1. The mean age of the patients was 53.9 years, ranged
from 24 to 99 years (standard deviation 14.078). All
histologically normal epithelia showed clearly uniform
membrane staining along the whole length of the crypt
(figure 1), which served as an internal positive control.
No background in the stroma or nuclear staining was
found at all.
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In all 30 of adenomas, beta catenin expression was  
present in both the cytoplasm (100%) and nuclear  
(73.3%). (table 2 and figure 2). Of the 24 cases with  
high grade dysplasia, intense cytoplasmic expression  
of beta catenin was found in 50% cases and intense  
nuclear expression present in 36.7% cases. There was  
no association between degree of dysplasia and  
expression of beta catenin (p > 0.05) (table 3).  
Beta catenin expression was also cytoplasmic  
(100%) and nuclear (96.7%) in all 30 carcinoma  
examined (table 2 and figure 3). The intensity of beta  
catenin staining in the cytoplasm and nuclear of the  
colorectal cancers was generally greater than those  
seen in adenomas (p < 0.000). There was no  
association between tumor differentiation and  
expression of beta catenin (p > 0.05) (table 3).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Membranous expression of beta catenin in colorectal 
normal mucosa  
The results of the immunostaining for beta catenin  
in each 30 normal mucosa, adenomas and carcinomas  
are summarized in table 2. In adenomas and  
carcinomas, three phenomena were observed: (a)  
membranous expression of beta catenin;  (b) the  
appearance of cytoplasmic expression of beta catenin; 
(c) the appearance of nuclear expression of beta 
catenin. 
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Figure 2. Membranous and cytoplasmic expression of beta catenin 
in colorectal adenoma 
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Table 1. Clinicopathologic characteristic 
Parameter Carcinoma  Adenoma  
n (%) n (%) 
Sex     
 - Male 16 (53.3) 12 (40.0) 
 - Female 14 (46.7) 18 (60.0) 
Age (year)   
 - <40  5 (16.7) 4 (13.3) 
 - 41 – 50 5 (16.7) 5 (16.7) 
 - 51 – 60 12 (40.0) 12 (40.0) 
 - >60 8 (26.7) 9 (30.0) 
Tumor location   
 - Right sided 7 (23.3) 2 (6.7) 
 - Left sided 14 (46.7) 8 (26.7) 
 - Rectum 9 (30.0) 20 (66.7) 
Histopathologic type   
 - Adenocarcinoma 29 (96.7)  
 - Mucinous carcinoma 1 (3.3)  
 - Tubular adenoma  4 (13.3) 
 - Tubulovilous adenoma  6 (20.0) 
 - Vilous adenoma  3 (10.0) 
Tumor diferentiation   
 - Well 13 (43.3)  
 - Moderate 9 (30.0)  
 - Poor 7 (23.3)  
Dysplasia degree   
 - Low grade  6 (20.0) 
 - High grade  24 (80.0) 
Tumor staging   
 - T1 0 (0)  
 - T2 8 (26.7)  
 - T3 22 (73.3)  
 - T4 0 (0)  
Lymph node status   
 - Nx 11 (36.7)  
 - N0 4 (13.3)  
 - N1 12 (40.0)  
 - N2 3 (10.0)   
 
 
 
Table 2. Beta catenin expression in normal mucosa, colorectal adenoma and carcinoma 
 Membranous Cytoplasmic Nuclear 
0 1 2 3 4 0 1-4 5-8 0 1-4 5-8 
Normal 
n 
(%) 
0  
(0) 
0  
(0) 
1 
(3.3) 
0  
(0) 
29 
(96.7) 
12 
(40) 
9  
(30) 
9  
(30) 
30 
(100) 
0  
(0) 
0  
(0) 
Adenoma 3 
(10) 
6 
(20) 
3 
(10) 
7 
(23.3) 
11 
(36.7) 
0  
(0) 
13 
(43.3) 
17 
(56.7) 
8 
(26.7) 
10 
(33.3) 
12 (40) 
Carcinoma 0  
(0) 
3 
(10) 
3 
(10) 
11 
(36.7) 
13 
(43.3) 
0 
 (0) 
5 
(16.7) 
25 
(83.3) 
1 (3.3) 12 
(40) 
17 
(56.7) 
  p = 0.000 p = 0.000 p = 0.000 
 
Table 3. Beta catenin expression in colorectal adenoma and carcinoma 
  Membranous Cytoplasmic Nuclear 
 
 0 1 2 3 4 0 1-4 5-8 0 1-4 5-8 
Dysplasia             
 Low grade n 
(%) 
0 
(0) 
0 
(0) 
1 
(3.3) 
2 
(6.7) 
3 
(10) 
0 
(0) 
4 
(13.3) 
2 
(6.7) 
2 
(6.7) 
3 
(10) 
1 
(3.3) 
 High grade 
3 
(10) 
6 
(20) 
2 
(6.7) 
5 
(16.7) 
8 
(26.7) 
0 
(0) 
9 
(30) 
15 
(50) 
6 
(20) 
7 
(23.3) 
11 
(36.7) 
Differentiated             
 Well 
n 
(%) 
0 
(0) 
2 
(6.7) 
1 
(3.3) 
4 
(13.3) 
6 
(20) 
0 
(0) 
3 
(10) 
10 
(33.3) 
1 
(3.3) 
4 
(13.3) 
8 
(26.7) 
 Moderate 
0 
(0) 
1 
(3.3) 
0 
(0) 
4 
(13.3) 
4 
(13.3) 
0 
(0) 
1 
(3.3) 
8 
(26.7) 
0 
(0) 
3 
(10) 
6 
(20) 
 Poor 
0 
(0) 
0 
(0) 
2 
(6.7) 
3 
(10) 
3 
(10) 
0 
(0) 
2 
(6.7) 
6 
(20) 
0 
(0) 
5 
(16.7) 
3 
10) 
   p > 0.05 p > 0.05 p > 0.05 
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DISCUSSION
Beta catenin is currently regarded as the
component that plays a role in the development of the
CRC which is the third leading cause of death from
cancer worldwide.6 Early detection and prompt
treatment will greatly affect the cure rate. This led to
the rapid development of diagnostic and prognostic
factors that can help us to detect asymptomatic CRC
and the precursor lesions, such as adenomas, and to
predict disease progression of CRC accurately.
This study was expected to provide evidence on
the relationship of beta catenin expression caused by
APC gene mutation in colorectal carcinogenesis. The
hypothesis underlying this study was that loss of
function of APC protein early in the process of colonic
carcinogenesis should result in the accumulation of
cytoplasmic and nuclear beta catenin that would be
detected by immunohistochemical analysis. We did not
expect the relationship would be perfect because other
mechanism that affects beta catenin degradation
pathway may occur, such as the mutation in the beta
catenin gene or activation of WNT signaling.
Our study showed significant increase regarding
beta catenin expression during the progression from
normal epithelium into carcinoma as reported by other
studies emphasizing its role as a key oncogenic factor
in colorectal carcinogenesis.7
Although the study did not find a relationship
between beta catenin expression and tumor
differentiation as in other study, but carcinomas with
mucinous components and poorly differentiated tumors,
generally indicate reduced beta catenin expression and
increased membrane expression as compared with
well-to-moderate carcinoma and non-mucinous
carcinoma.8 Such finding suggests that beta catenin
serves to maintain the state of cell differentiation.8
Hao et al demonstrated that nuclear beta catenin
expression was found in 6/46 (13%) cases of aberrant
crypt foci (ACF), which was associated with the
progression from ACF into adenoma and carcinoma.9
Another study from Wong et al found nuclear beta
catenin expression in 5/60 cases (8%) colorectal polyps
(Peutz-Jegher and hyperplastic polyps).10 It indicated
the presence of beta catenin deregulation that occur
early in colorectal carcinogenesis.9,10
In addition to the nuclear expression, our study also
showed both cytoplasmic and membrane expressions
of beta catenin, which increases with the progression
of carcinogenesis. Similar results were also obtained
from Elzagheid et al that found a nearly 100%
expression of beta catenin in the membrane and
cytoplasm of the CRC and adenoma.11 Beta catenin
is a multifunctional protein complex, which is a
component of adhesion between cells and part of the
WNT signaling pathway to be degraded by APC
degradation complex - Axin-GSK-3-beta. In cells with
two alleles, APC mutant beta catenin degradation does
not occur and cause increased accumulation of beta
catenin in cytoplasm.12
Our study demonstrated that there is no association
between the location of beta catenin expression
(membrane, cytoplasm, and nucleus) and the existing
clinical variables (age, gender, and location of the
tumor). Some studies have also found similar results
except for the tumor location. Kawasaki et al and
Elzagheid et al reported increased nuclear and
cytoplasm expression of beta catenin in the right-sided
tumor location compared to the left-sided and
rectum.11,13 Different molecular mechanisms are
involved in colorectal carcinogenesis, in which the
adenoma carcinoma sequence of carcinogenesis
pathway generally occurs on the left side of the colon
and rectum; while the mutator phenotype occurs in
the right side.13
The relationship between the location of beta-
catenin expression and clinical outcome is still a subject
of controversy. In a study involving 60 cases of CRC,
nuclear beta catenin expression predicted a poorer
survival.14 Another study in 650 cases of CRC showed
that beta catenin expression was not associated with
survival rates.15 A recent study involving 60 cases of
CRC found no predictive value of nuclear beta catenin
expression, but its expression on the membrane,
cytoplasm and nucleus was associated with a better
differentiation and lower stage of disease.8 In a study
with 95 cases of stage IV CRC, the membrane beta
catenin expression was associated with a higher cure
rates.11 Recent data show that suppression of beta
catenin may inhibit the development of mutant APC
CRC.16-18
CONCLUSION
It can be concluded that beta catenin is a
component that plays a role in the development of the
CRC and that the subcellular location of beta-catenin
may describe its oncogenic activity. Further studies
are needed to recognize the relationship of other factors
that also play roles in Wnt signaling pathway/beta
catenin, including APC protein, beta catenin, axin and
GSK-3-beta in order to get a comprehensive
understanding of beta-catenin activity that can be used
for the development of preventive agent in the future.
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